Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEHRG214 in HIV-Infected Patients
NCT00385567Phase 2Terminated
- Sponsor
- Virionyx Corporation Limited
- Start
- Jan 2007
- Primary completion
- Sep 2008
- Modality
- Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of PEHRG214 in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Virionyx Corporation Limited. Primary endpoints: Decrease in viral load >= 1.0 log10 at 16 weeks, Positive changes in CD4 count at 16 weeks and 3 more. Started Jan 2007; status: terminated.
02
Drugs
PEHRG214
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00385567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00385567.